Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-Star001 in Nectin-4-positive Advanced Solid Tumors
NCT07101549Phase 1Not yet recruiting
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of R-Star001 in solid tumor (advanced stage). Primary endpoints: Dose limiting toxicity at 28 days, Adverse events at 1 year and 1 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
R-Star001
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07101549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101549.